Key Takeaways
- • Private equity healthcare deal volume has declined 18.5% year-over-year as of Q2 2026, with private equity takeovers of physician groups down by approximately 50%, driven by tightened state regulatory oversight.
- • Over a dozen states have enacted new laws restricting private equity ownership and control in healthcare, targeting "friendly PC" structures, management services organizations (MSOs), and common corporate practice models that have enabled rapid consolidation over the past decade.
- • California's recent statute prohibits private investors from interfering with physician clinical judgment and bars contract terms that restrict provider competition or suppress speech about quality of care, utilization, and revenue strategies—while preserving traditional sale-of-business noncompetes and empowering the attorney general to enforce violations.
- • State regulatory action is reshaping the corporate practice of medicine (CPOM) landscape by increasing transaction transparency, constraining unlicensed entity control over professional practices, and expanding enforcement mechanisms—fundamentally altering deal structures for private equity, hedge funds, REITs, and MSOs operating in healthcare.
- • Oregon and other states are implementing comprehensive structural reforms that go beyond California's approach, signaling a sustained policy shift toward limiting private equity's influence on clinical autonomy, affordability, and continuity of care.
Summary
State-level regulatory intervention is reshaping the private equity healthcare market. Private equity deal activity has contracted sharply, with healthcare deal volumes declining 18.5% year-over-year and physician group takeovers falling by approximately 50%, according to recent market data. This contraction reflects a coordinated policy response across more than a dozen states that have enacted new laws constraining private equity ownership structures and increasing oversight of healthcare transactions.
The regulatory movement is rooted in concerns about the effects of rapid private equity consolidation on patient care and provider autonomy. As private equity's footprint in healthcare expanded significantly over the past decade, state lawmakers and attorneys general grew concerned about affordability pressures, continuity of care disruptions, and erosion of clinical autonomy. Physicians employed by private equity-backed entities report facing incentives to increase patient throughput and reduced latitude in making referrals outside corporate networks, intensifying scrutiny of how ownership structures influence clinical decision-making.
In response, states are reviving and modernizing corporate practice of medicine (CPOM) doctrines—long-standing legal principles that restrict unlicensed individuals or entities from owning professional practices or exerting control over clinical decisions. California has codified these principles through recent legislation that prohibits private investors from interfering with physician and dentist professional judgment. The statute goes further than traditional CPOM rules by explicitly barring contract provisions that restrict provider competition post-departure or that discourage providers from speaking about quality of care, utilization concerns, ethical issues, or revenue strategies. Notably, the law preserves enforceable sale-of-business noncompetes while granting the state attorney general authority to enforce the new restrictions through equitable remedies.
Oregon is implementing even more comprehensive structural reforms that represent a deeper rethinking of the "friendly PC" and MSO business models that private equity has relied on to structure healthcare acquisitions. These state-level interventions are creating a patchwork of new guardrails that increase transaction visibility, constrain MSO roles, and expand enforcement mechanisms. The cumulative effect is a fundamental remake of the regulatory environment governing private equity, hedge funds, REITs, and management services organizations seeking to acquire or control healthcare providers—signaling that deal structures and ownership models that enabled rapid consolidation over the past decade are no longer viable under emerging state law.
The regulatory movement is rooted in concerns about the effects of rapid private equity consolidation on patient care and provider autonomy. As private equity's footprint in healthcare expanded significantly over the past decade, state lawmakers and attorneys general grew concerned about affordability pressures, continuity of care disruptions, and erosion of clinical autonomy. Physicians employed by private equity-backed entities report facing incentives to increase patient throughput and reduced latitude in making referrals outside corporate networks, intensifying scrutiny of how ownership structures influence clinical decision-making.
In response, states are reviving and modernizing corporate practice of medicine (CPOM) doctrines—long-standing legal principles that restrict unlicensed individuals or entities from owning professional practices or exerting control over clinical decisions. California has codified these principles through recent legislation that prohibits private investors from interfering with physician and dentist professional judgment. The statute goes further than traditional CPOM rules by explicitly barring contract provisions that restrict provider competition post-departure or that discourage providers from speaking about quality of care, utilization concerns, ethical issues, or revenue strategies. Notably, the law preserves enforceable sale-of-business noncompetes while granting the state attorney general authority to enforce the new restrictions through equitable remedies.
Oregon is implementing even more comprehensive structural reforms that represent a deeper rethinking of the "friendly PC" and MSO business models that private equity has relied on to structure healthcare acquisitions. These state-level interventions are creating a patchwork of new guardrails that increase transaction visibility, constrain MSO roles, and expand enforcement mechanisms. The cumulative effect is a fundamental remake of the regulatory environment governing private equity, hedge funds, REITs, and management services organizations seeking to acquire or control healthcare providers—signaling that deal structures and ownership models that enabled rapid consolidation over the past decade are no longer viable under emerging state law.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.